Point of Collection Drug Testing: What TPAs and CRAs Need to Know to Build Smarter, More Effective Testing Programs
Understanding device reliability, program design, and the role of laboratory testing in today’s screening environment.
Point-of-Collection Testing (POCT) drug tests have become a widely used tool in workplace testing programs, particularly in non-DOT environments. Their ability to deliver results within minutes makes them attractive to employers that need fast answers for hiring decisions, reasonable-suspicion situations, or post-accident testing.
While POCT devices offer clear operational advantages, they also come with important considerations. For TPAs and CRAs, understanding how these tests fit into a broader program is essential to delivering reliable, scalable, and client-ready solutions.
The Advantages of POCT
The most obvious advantage of POCT drug tests is speed. Results are typically available within minutes, allowing employers to move forward quickly with employment decisions or safety-related investigations.
POCT can also be cost-effective, particularly when negative results are common. In many cases, a negative POCT result can eliminate the need for laboratory analysis, reducing overall testing costs.
From an operational standpoint, POCT devices also provide flexibility. Testing can be performed on-site or in locations where immediate access to a laboratory collection facility may not be practical. For certain use cases, this convenience makes POCT an efficient solution.
The Considerations of POCT Drug Testing
Despite these advantages, POCT drug tests are ultimately screening tools—not confirmatory tests. Any non-negative result must still be sent to a certified laboratory for confirmation using more precise testing technologies.
POCT also introduces a greater reliance on collector training and procedural consistency. Because tests are performed and interpreted at the collection site, timing, specimen handling, and result interpretation all play a role in the outcome.
Additionally, POCT results typically provide less detailed documentation and reporting compared to laboratory-based testing, which can be an important consideration for programs focused on defensibility and compliance.
Not All POCT Devices Are Created Equal
Another important factor in POCT reliability is the device itself. While most rapid testing devices operate using similar immunoassay technology, manufacturing quality, design, and quality control standards can vary significantly between manufacturers.
Higher-quality devices are typically designed with clearer result indicators, improved reagent stability, and stronger quality control processes. These factors help minimize inconsistencies and reduce the likelihood of invalid tests.
Lower-cost devices may appear similar on the surface, but differences in reliability often become more apparent in high-volume environments.
For TPAs and CRAs, these decisions carry added importance. The devices you choose are not just internal tools—they become part of the solutions you deliver to your clients. Even small differences in performance can impact client experience, operational efficiency, and scalability.
When the Device Itself Fails
One often overlooked aspect of POCT reliability is device failure—when the test cannot produce a valid result.
Most POCT drug testing devices include an internal control line to confirm the test is functioning properly. If this control line does not appear, the test is considered invalid and unusable, regardless of the specimen result.
While all manufacturers may experience occasional defects, invalid rates can vary across devices due to factors such as manufacturing consistency, storage conditions, and strip stability.
When an invalid test occurs, it can lead to:
- Additional specimen collections
- Delays in hiring or safety-related decisions
- Increased program costs
- Frustration for both collectors and donors
For high-volume programs, even a small percentage of invalid devices can create meaningful operational disruption.
The Role of Confirmatory Laboratory Testing
Because of these considerations, POCT drug testing should be viewed for what it is: a screening tool—not a final answer.
Laboratory-based testing remains the gold standard for drug testing, providing a level of accuracy, reliability, and defensibility that rapid tests cannot match. Certified laboratories utilize advanced analytical technologies such as gas chromatography and mass spectrometry, delivering precise results supported by full chain-of-custody documentation and Medical Review Officer (MRO) verification.
What often gets overlooked, however, is how much laboratory turnaround times have improved.
There is a common perception that POCT dramatically speeds up the hiring or screening process. In reality, that’s not always the case. When drug testing is just one component of a broader workflow—alongside background checks, occupational health services, or onboarding steps—the “instant” result from a POCT device rarely determines the overall timeline.
In many situations, organizations are optimizing for speed in one part of the process while the rest of the program operates on a longer timeline.
For TPAs and CRAs, this highlights the importance of asking a different question:
What creates the most efficient, reliable, and defensible overall program?
That answer often leads to laboratory testing as the foundation, with POCT used selectively where it adds value—not simply where it appears faster.
The most effective programs are designed holistically, with each component working together to deliver a consistent, scalable, and client-ready solution.
Choosing the Right Approach
POCT drug testing can play an important role in certain scenarios, particularly when rapid results are needed. However, organizations should recognize that device quality varies, proper administration is critical, and invalid results can occur.
For these reasons, many successful programs use POCT strategically while continuing to rely on laboratory-based testing as the foundation of their overall approach.
At i3screen, we work with organizations across a wide range of testing environments and consistently see the most effective programs built around the right combination of reliable testing methods, strong operational workflows, and trusted laboratory partners.
Final Thoughts
There is no shortage of POCT drug testing devices on the market today—and the differences between them can be significant. For TPAs and CRAs, these decisions go beyond internal operations. The products you choose ultimately become part of the solutions you deliver to your clients.
Usability, reliability, and overall quality vary widely across manufacturers. While cost is always a factor, selecting devices based solely on price can introduce unnecessary risk—impacting client experience, increasing operational friction, and creating avoidable challenges at scale. Taking the time to evaluate real-world performance and align device selection with your service model is critical.
Equally important is ensuring that your testing program is supported by the right infrastructure. The i3screen platform is designed to work with a wide range of POCT devices, giving TPAs and CRAs the flexibility to support different client needs while maintaining consistent workflows, strong record retention, and seamless laboratory confirmations when required.
At the end of the day, your clients aren’t just relying on you for speed—they’re relying on you for reliable, defensible results and a program that works.
If you’re evaluating the devices you offer or looking to strengthen how POCT fits into your overall program, we’re always available to share what we’re seeing across the industry and help you think through the best approach.
